Alberto Piubello
Overview
Explore the profile of Alberto Piubello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cadmus S, Akinseye V, Olagunju T, Makolo A, Falodun O, Lawal O, et al.
Pan Afr Med J
. 2025 Mar;
49:87.
PMID: 40027092
Introduction: tuberculosis (TB) remains a disease of global health importance. GeneXpert has emerged as a useful tool for the diagnosis of drug resistant TB (DR-TB). We determined the risk factors...
2.
de Jong B, Nourdine S, Bergeman A, Salim Z, Grillone S, Braet S, et al.
PLoS Med
. 2024 Oct;
21(10):e1004453.
PMID: 39432509
Background: To reduce leprosy risk in contacts of patients with leprosy by around 50%, the World Health Organization (WHO) recommends leprosy post-exposure prophylaxis (PEP) using single-dose rifampicin (SDR). Results from...
3.
Bergeman A, Nourdine S, Piubello A, Salim Z, Braet S, Baco A, et al.
Clin Transl Sci
. 2024 Jul;
17(8):e13861.
PMID: 39075882
Some anti-mycobacterial drugs are known to cause QT interval prolongation, potentially leading to life-threatening ventricular arrhythmia. However, the highest leprosy and tuberculosis burden occurs in settings where electrocardiographic monitoring is...
4.
Silva D, Centis R, DAmbrosio L, Mello F, Pereira G, Aguirre S, et al.
J Bras Pneumol
. 2024 Jul;
50(3):e20240077.
PMID: 38985022
No abstract available.
5.
Younoussa A, Samidine S, Bergeman A, Piubello A, Attoumani N, Grillone S, et al.
BMC Infect Dis
. 2023 May;
23(1):310.
PMID: 37161571
Background: Leprosy is an ancient infectious disease with an annual global incidence of around 200,000 over the past decade. Since 2018, the World Health Organization (WHO) recommends single-dose rifampicin as...
6.
Souleymane M, Kadri S, Piubello A, Tsoumanis A, Soumana A, Issa H, et al.
Int J Infect Dis
. 2023 May;
133:78-81.
PMID: 37150352
Objectives: High-dose rifampicin (R) and isoniazid (H) are known to be safe but were not yet combined in a single regimen. The primary objective of the TRIple-DOse RE-treatment (TRIDORE) study...
7.
Souleymane M, Decroo T, Soumana A, Maman Lawan I, Gagara-Issoufou A, Halidou-Moussa S, et al.
Trials
. 2022 Dec;
23(1):1011.
PMID: 36514153
Background: Rifampicin-resistant tuberculosis (RR-TB) treatment requires combination treatment, which frequently causes serious adverse events and globally results in not much more than 60% treatment success. In Niger, a high cure...
8.
Jouego C, Gils T, Piubello A, Mbassa V, Kuate A, Ngono A, et al.
Int J Infect Dis
. 2022 Sep;
124:81-88.
PMID: 36108960
Objectives: To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in...
9.
Toft A, Dahl V, Sifna A, Ige O, Schwoebel V, Souleymane M, et al.
Int J Infect Dis
. 2022 Aug;
124 Suppl 1:S107-S116.
PMID: 36007688
Objectives: We aimed to investigate published data on treatment outcomes of multidrug-resistant (MDR)/rifampicin-resistant tuberculosis (TB) in Central and West Africa because these, to the best of our knowledge, are sparsely...
10.
Souleymane M, Decroo T, Mamadou S, Soumana A, Lawan I, Gagara-Issoufou A, et al.
Int Health
. 2022 Apr;
15(3):258-264.
PMID: 35420123
Background: Outcomes of retreatment for rifampicin-resistant tuberculosis (RR-TB) are rarely reported. We report 'definitive outcomes' after a cascade approach to RR-TB treatment. After a bacteriologically adverse outcome for the 9-months...